Forum Pharmaceuticals Inc.
Records under this name other than patents Forum Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Forum Pharmaceuticals Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,802,927 | Oxadiazine Compounds and Methods of Use Thereof now held by Denali Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 9,273,044 | Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate Lapsed on the fee record Ended Mar 1, 2024 · High confidence | Lapsed on the fee record | Ended Mar 1, 2024 | High confidence |
| US 10,428,062 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors now held by Axovant Sciences GmbH Lapsed on the fee record Ended Oct 1, 2023 · High confidence | Lapsed on the fee record | Ended Oct 1, 2023 | High confidence |
| US 9,108,961 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate held by Envivo Pharmaceuticals, Inc. Lapsed on the fee record Ended Aug 18, 2023 · High confidence | Lapsed on the fee record | Ended Aug 18, 2023 | High confidence |
| US 10,370,370 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors now held by Axovant Sciences GmbH Lapsed on the fee record Ended Aug 6, 2023 · High confidence | Lapsed on the fee record | Ended Aug 6, 2023 | High confidence |
| US 8,815,933 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof Lapsed on the fee record Ended Aug 26, 2022 · Medium confidence | Lapsed on the fee record | Ended Aug 26, 2022 | Medium confidence |
| US 8,710,227 | Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate Lapsed on the fee record Ended Apr 29, 2022 · High confidence | Lapsed on the fee record | Ended Apr 29, 2022 | High confidence |
| US 8,642,638 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceuticall Acceptable Salts Thereof Lapsed on the fee record Ended Feb 4, 2022 · Medium confidence | Lapsed on the fee record | Ended Feb 4, 2022 | Medium confidence |
| US 8,569,354 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof Lapsed on the fee record Ended Oct 29, 2021 · Medium confidence | Lapsed on the fee record | Ended Oct 29, 2021 | Medium confidence |
| US 9,725,453 | Imidazotriazinone Compounds now held by Ironwood Pharmaceuticals, Inc. Lapsed on the fee record Ended Aug 8, 2021 · High confidence | Lapsed on the fee record | Ended Aug 8, 2021 | High confidence |